Protagonist Therapeutics Inc (PTGX)

Payables turnover

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Cost of revenue (ttm) US$ in thousands 39,796 33,491 32,071 31,310 29,829 31,739 32,367 32,722 31,746 27,196 24,930 22,565 20,027 18,638 17,751 16,875 16,561 15,749 15,159 14,505
Payables US$ in thousands 3,507 772 1,252 4,573 4,021 3,640 4,715 1,412 7,159 1,600 706 7,905 2,732 3,075 2,797 2,855 3,704 2,790 1,583 2,787
Payables turnover 11.35 43.38 25.62 6.85 7.42 8.72 6.86 23.17 4.43 17.00 35.31 2.85 7.33 6.06 6.35 5.91 4.47 5.64 9.58 5.20

March 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $39,796K ÷ $3,507K
= 11.35

Protagonist Therapeutics Inc's payables turnover ratio fluctuated over the past few quarters. The payables turnover ratio ranged from a low of 2.85 to a high of 43.38 during this period. A high payables turnover ratio indicates that the company is effectively managing its accounts payable by paying its suppliers quickly. Conversely, a low ratio may suggest that the company is taking longer to pay its suppliers.

The significant variation in the payables turnover ratio over the quarters may indicate changes in the company's payment policies or the timing of supplier payments. It is essential to analyze the reasons behind these fluctuations to understand the company's liquidity position and its relationships with suppliers. Additionally, comparing the payables turnover ratio with industry benchmarks can provide further insights into Protagonist Therapeutics Inc's financial performance and efficiency in managing its payables.


Peer comparison

Mar 31, 2024